Fuzeon Side Effects
Generic Name: enfuvirtide
Please note - some side effects for Fuzeon may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
Side Effects of Fuzeon - for the Consumer
Fuzeon
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Fuzeon:
Seek medical attention right away if any of these SEVERE side effects occur when using Fuzeon:Constipation; diarrhea; dizziness; injection site reactions (pain, redness, itching, bleeding, bruising, hardened skin, or bumps); loss of appetite; muscle pain; nausea; tiredness; trouble sleeping; weakness.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); anxiety; blood in the urine; depression; fever with vomiting and skin rash; flu-like symptoms; severe of persistent stomach pain; signs of infection at the injection site (eg, oozing, swelling, increasing heat); signs of pneumonia (eg, cough with fever, rapid breathing, shortness of breath); stomach pain; swelling of the feet.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
TopFuzeon Side Effects - for the Professional
Fuzeon
The following adverse reactions are discussed in greater detail in other sections:
- Administration with Biojector® 2000 [see Warnings and Precautions (5.2)]
- Pneumonia [see Warnings and Precautions (5.3)]
- Hypersensitivity Reactions [see Warnings and Precautions (5.4)]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The overall safety profile of Fuzeon is based on 2131 subjects who received at least 1 dose of Fuzeon during various clinical trials. This includes 2051 adults, 658 of whom received the recommended dose for greater than 48 weeks, and 63 pediatric subjects.
Assessment of treatment-emergent adverse events is based on the pooled data from the two randomized, controlled, open-label, multicenter trials in treatment-experienced subjects, T20-301 (TORO 1) and T20-302 (TORO 2).
Local Injection Site Reactions
Local injection site reactions were the most frequent adverse events associated with the use of Fuzeon. In T20-301 and T20-302, 98% of subjects had at least one local injection site reaction (ISR). A total of 7% of subjects discontinued treatment with Fuzeon because of ISRs (4%) or difficulties with injecting Fuzeon (3%) such as injection fatigue and inconvenience. Eighty-five percent of subjects experienced their first ISR during the initial week of treatment; ISRs continued to occur throughout treatment with Fuzeon. For most subjects the severity of signs and symptoms associated with ISRs did not change during the 48 weeks of treatment. The majority of ISRs were associated with erythema, induration, the presence of nodules or cysts, and mild to moderate pain at the injection site (Table 2). In addition, the average duration of individual ISRs was between three and seven days in 41% of subjects and more than seven days in 24% of subjects. Also, the numbers of ISRs per subject at any one time was between six to 14 ISRs in 26% of subjects and more than 14 ISRs in 1.3% of subjects. Infection at the injection site (including abscess and cellulitis) was reported in 1.7% of adult subjects.
| N=663 | |||
|---|---|---|---|
| Event Category | Any Severity Grade | % of Subjects with Grade 3 Reactions | % of Subjects with Grade 4 Reactions |
|
|||
| Pain/Discomfort * | 96% | 11% | 0% |
| Induration | 90% | 39% >25 but <50 mm |
18% ≥50 mm |
| Erythema | 91% | 22% >50 but <85 mm |
10% ≥85 mm |
| Nodules and Cysts | 80% | 23% >3 cm average diameter |
0.2% Draining |
| Pruritus † | 65% | 3% | NA |
| Ecchymosis | 52% | 5% >3 but ≤5 cm |
2% >5 cm |
Other Adverse Events
In T20-301 and T20-302, after study week 8, subjects on background alone who met protocol defined criteria for virological failure were permitted to revise their background regimens and add Fuzeon. Exposure on Fuzeon+background was 557 patient-years, and to background alone 162 patient-years. Due to this difference in exposure, safety results are expressed as the number of patients with an adverse event per 100 patient-years of exposure. For Fuzeon+background, adverse events are also displayed by percent of subjects.
The events most frequently reported in subjects receiving Fuzeon+background regimen, excluding ISRs, were diarrhea (38 per 100 patient-years or 31.7%), nausea (27 per 100 patient-years or 22.8%), and fatigue (24 per 100 patient-years or 20.2%). These events were also commonly observed in subjects that received background regimen alone: diarrhea (73 per 100 patient-years), nausea (50 per 100 patient-years), and fatigue (38 per 100 patient-years).
Treatment-emergent adverse events, regardless of causality and excluding ISRs, from Phase 3 studies are summarized for adult subjects, in Table 3. Any Grade 2 or above events occurring at ≥2 percent of subjects and at a higher rate in subjects treated with Fuzeon are summarized in Table 3; events that occurred at a higher rate in the control arms are not displayed.
Rates of adverse events for subjects who switched to Fuzeon after virological failure were similar.
| Adverse Event (by System Organ Class) | Fuzeon+Back-ground Regimen (N=663) |
Fuzeon+Back-ground Regimen (N=663) |
Background Regimen (N=334) |
|---|---|---|---|
| 663 subjects total | 557 total patient-years | 162 total patient-years | |
| % frequency | rate/100 patient-years | rate/100 patient-years | |
| Weight Decreased | 6.6% | 7.9 | 6.2 |
| Sinusitis | 6.0% | 7.2 | 4.9 |
| Abdominal Pain | 3.9% | 4.7 | 3.7 |
| Cough | 3.9% | 4.7 | 2.5 |
| Herpes Simplex | 3.5% | 4.1 | 3.7 |
| Appetite Decreased | 3.2% | 3.8 | 2.5 |
| Pancreatitis | 3.0% | 3.6 | 2.5 |
| Pain in Limb | 2.9% | 3.4 | 3.1 |
| Pneumonia | 2.7% | 3.2 | 0.6 |
| Myalgia | 2.7% | 3.2 | 1.2 |
| Influenza-Like Illness | 2.4% | 2.9 | 1.9 |
| Folliculitis | 2.4% | 2.9 | 2.5 |
| Anorexia | 2.3% | 2.7 | 1.9 |
| Dry Mouth | 2.1% | 2.5 | 1.9 |
| Conjunctivitis | 2.0% | 2.3 | 1.9 |
Less Common Events
The following adverse events have been reported in 1 or more subjects; however, a causal relationship to Fuzeon has not been established.
Immune System Disorders: worsening abacavir hypersensitivity reaction
Renal and Urinary Disorders: glomerulonephritis; tubular necrosis; renal insufficiency; renal failure (including fatal cases)
Blood and Lymphatic Disorders: thrombocytopenia; neutropenia; fever; lymphadenopathy
Endocrine and Metabolic: hyperglycemia
Infections: sepsis; herpes simplex
Nervous System Disorders: taste disturbance; Guillain-Barre syndrome (fatal); sixth nerve palsy; peripheral neuropathy
Cardiac Disorders: unstable angina pectoris
Gastrointestinal Disorders: constipation; abdominal pain upper
General: asthenia
Hepatobiliary Disorders: toxic hepatitis; hepatic steatosis
Investigations: increased amylase; increased lipase; increased AST; increased GGT; increased triglycerides
Psychiatric Disorders: insomnia; depression; anxiety; suicide attempt
Respiratory, Thoracic, and Mediastinal Disorders: pneumopathy; respiratory distress; cough
Skin and Subcutaneous Tissue Disorders: pruritus
Laboratory Abnormalities
Table 4 shows the treatment-emergent laboratory abnormalities that occurred in at least 2 subjects per 100 patient-years and more frequently in those receiving Fuzeon+background regimen than background regimen alone from T20-301 and T20-302.
| Laboratory Parameters | Grading | Fuzeon+Back-ground Regimen (N=663) |
Fuzeon+Back-ground Regimen (N=663) |
Background Regimen (N=334) |
|---|---|---|---|---|
| 663 subjects total | 557 total patient-years | 162 total patient-years | ||
| % frequency | rate/100 patient-years | rate/100 patient-years | ||
|
||||
| Eosinophilia | ||||
| 1-2 X ULN (0.7 × 109/L) | 0.7-1.4 × 109/L | 9.1% | 10.8 | 3.7 |
| >2 X ULN (0.7 × 109/L) | >1.4 × 109/L | 1.8% | 2.2 | 1.8 |
| ALT | ||||
| Grade 3 | >5-10 × ULN | 4.1% | 4.8 | 4.3 |
| Grade 4 | >10 × ULN | 1.2% | 1.4 | 1.2 |
| Creatine Phosphokinase (U/L) | ||||
| Grade 3 | >5-10 × ULN | 6.9% | 8.3 | 8.0 |
| Grade 4 | >10 × ULN | 2.6% | 3.1 | 8.6 |
Adverse Events in Pediatric Patients
Fuzeon has been studied in 63 pediatric subjects 5 through 16 years of age with duration of Fuzeon exposure ranging from 1 dose to 134 weeks. Adverse experiences seen during clinical trials were similar to those observed in adult subjects, although infections at site of injection (cellulitis or abscess) were more frequent in adolescents than in adults, with 4 events occurring in 3 of 28 (11%) subjects.
TopSide Effects by Body System - for Healthcare Professionals
General
In general, the most common side effects in patients receiving enfuvirtide and a background regimen have included injection site reactions, diarrhea, nausea, and fatigue.
Local
Local side effects have been reported in 98% of patients and have included pain/discomfort at the injection site (96%), induration (90%), erythema (91%), nodules and cysts (80%), pruritus (65%), ecchymosis (52%), injection site infection (including abscess and cellulitis, 1.7%), minor local bleeding, injection site reactions, injection site mass, injection site inflammation, and injection site edema. The administration of enfuvirtide using the Biojector (R) 2000 needle-free device has been associated with hematomas, bruising, tenderness, and swelling. At least one case of localized amyloidosis at the site of enfuvirtide injection has been reported.
Gastrointestinal
Gastrointestinal side effects associated with enfuvirtide and a background regimen have included diarrhea (31.7%), nausea (22.8%), abdominal pain (3.9%), dry mouth (2.1%), pancreatitis (3.0%), abdominal distension, vomiting, flatulence, and oral candidiasis. Constipation, increased amylase, and increased lipase have also been reported; however, causality has not been determined.
Hypersensitivity
Hypersensitivity side effects have included hypersensitivity reactions in less than 1% of patients and in some cases have recurred upon rechallenge. Signs and symptoms of reactions have included rash, fever, nausea, vomiting, chills, rigors, hypotension, elevated liver transaminases, primary immune complex reaction, respiratory distress, glomerulonephritis, and Guillain-Barre syndrome. Worsening of abacavir hypersensitivity reaction has been reported; however, causality has not been established. General allergic reaction (not defined as hypersensitivity reaction) has also been reported.
Metabolic
Metabolic side effects associated with enfuvirtide in combination with a background regimen have included decreased weight (6.6%), decreased appetite (3.2%), anorexia (2.3%), and hyperlipemia. Increased triglycerides and hyperglycemia have also been reported; however, causality has not been established.
Nervous system
Nervous system side effects associated with enfuvirtide and a background regimen have included peripheral neuropathy, taste disturbance, sixth nerve palsy and fatal Guillain-Barre syndrome have also been reported; however, causality has not been established. Dizziness, headache, and epidural abscess have also been reported. The administration of enfuvirtide using the Biojector (R) 2000 needle-free device has been associated with neuralgia and/or paresthesia (nerve pain) lasting up to 6 months when injected at sites where large nerves run close to the skin.
Other
Other side effects associated with enfuvirtide and a background regimen have included fatigue (20.2%), herpes simplex (3.5%), influenza-like illness (2.4%), malaise, fever, and chills. Asthenia and sepsis have also been reported; however, causality has not been determined.
Psychiatric
Psychiatric side effects associated with enfuvirtide and a background regimen have included insomnia, depression, anxiety, and suicide attempt; however, causality has not been established. Abnormal thinking and agitation have also been reported.
Respiratory
Respiratory side effects associated with enfuvirtide and a background regimen have included cough (3.9%), sinusitis (6.0%), bronchitis, nasopharyngitis, and upper respiratory tract infection. Pneumonia (2.7%), including fatalities, pneumopathy, and respiratory distress have also been reported; however, causality has not been determined. Patients should be carefully monitored for symptoms of pneumonia.
Dermatologic
Dermatologic side effects associated with enfuvirtide and a background regimen have included folliculitis (2.4%), dermatitis, pruritus, dry skin, skin papilloma, skin discoloration, and rash (not defined as hypersensitivity reaction).
Musculoskeletal
Musculoskeletal side effects associated with enfuvirtide and a background regimen have included myalgia (2.7%), limb pain (2.9%), and increased creatine phosphokinase (Grade 3, 6.9%; Grade 4, 2.6%). Vertebral osteomyelitis has also been reported.
Ocular
Ocular side effects associated with enfuvirtide and a background regimen have included conjunctivitis (2.0%).
Hematologic
Hematologic side effects associated with enfuvirtide and a background regimen have included eosinophilia (1 to 2 times ULN, 9.1%; greater than 2 times ULN, 1.8%), leukopenia, and anemia. Thrombocytopenia, neutropenia, and lymphadenopathy have also been reported; however, causality has not been established.
Renal
Renal side effects have included glomerulonephritis, tubular necrosis, renal insufficiency, and renal failure (including fatalities); however, causality has not been established.
Hepatic
Hepatic side effects associated with enfuvirtide and a background regimen have included increased ALT (Grade 3, 4.1%; Grade 4, 1.2%). Increased AST, increased GGT, toxic hepatitis, and hepatic steatosis have also been reported; however, causality has not been determined.
Cardiovascular
Cardiovascular side effects associated with enfuvirtide and a background regimen have included unstable angina pectoris; however, causality has not been established.
Genitourinary
Genitourinary side effects have included hematuria.
Immunologic
Immunologic side effects have included opportunistic infections and general infectious diseases.
TopMore Fuzeon resources
- Fuzeon Prescribing Information (FDA)
- Fuzeon Monograph (AHFS DI)
- Fuzeon Advanced Consumer (Micromedex) - Includes Dosage Information
- Fuzeon Consumer Overview
- Fuzeon MedFacts Consumer Leaflet (Wolters Kluwer)
- Enfuvirtide Professional Patient Advice (Wolters Kluwer)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
